Oppenheimer Holdings' profit margin is lacking behind key peers, particularly Morgan Stanley, who is also a key competitor.

Fintel reports that on March 5, 2025, Oppenheimer initiated coverage of Abeona Therapeutics (NasdaqCM:ABEO) with a Outperform ...

Oppenheimer analyst Brian Bittner reiterated a Buy rating on Yum! Brands (YUM – Research Report) today and set a price target of $185.00. The ...

Christopher Nolan's Oppenheimer returned to theaters and is set to overtake Zack Snyder's Batman v. Superman as it climbs toward $1 billion.

Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) today and set a price target of ...

If you missed Oppenheimer in IMAX you can get another chance to see it this weekend with a one-week USA and Canada rerelease ...

Shogun star Cosmo Jarvis has joined the cast of Christopher Nolan's The Odyssey - and I don't think the cast list is ever ...

Tactile Systems Technology, Inc. ("Tactile Medical”; the "Company”) (Nasdaq: TCMD), a medical technology company providing ...

Oppenheimer analyst Matthew Biegler says Olema Oncology (OLMA) published a revised corporate deck today which included an update from the ...

David Krumholtz unfortunately developed a rare and extremely dangerous disease, and he feels the need to publicly alert ...

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...

The audience for the highest honors in Hollywood fell 7% from the 2024 ceremony, when 19.5 million people tuned in to see ...